<p>(TheNewswire)</p>
<p>温哥华，不列颠哥伦比亚省 –2026 年 3 月 11 日– TheNewswire – NeuroThera</p>
<p>Labs Inc.（以下简称 “公司” 或 “NeuroThera”），是一家临床阶段的生物技术公司，且为 SciSparc Ltd.（纳斯达克代码：SPRC）的控股子公司，已通过根据《专利合作条约》（PCT）发布国际专利申请，推进与 Clearmind Medicine Inc.的合作，旨在治疗与体重减轻和代谢功能障碍相关的脂肪肝病（MASLD，前称脂肪肝病）的新型组合疗法。</p>
<p>该专利的发布突显了 5-美氧基-2-氨基吲哚（MEAI）与棕榈酰乙醇胺（PEA）组合的潜力，能够为全球面临的两大健康挑战提供安全、非致幻的神经塑性治疗：肥胖，影响全球超过 8.9 亿成年人，以及 MASLD，影响约 30% 的全球成年人口。</p>
<p>此外，由于该组合的假定作用机制，这种治疗选择可能比 GLP-1 激动剂提供更安全、更简单和更具成本效益的选择，适用于肥胖和 MASLD。</p>
<p>通过将 Clearmind 的 MEAI 平台与 NeuroThera 的 PEA 结合，这两家公司希望满足在肥胖和肝脏健康领域对有效、耐受性好和安全治疗的日益增长的需求。这正值全球减肥药物市场快速增长之际，预计 2025 年市场价值约为 370 亿美元，</p>
<p>并预计到 2035 年将达到 2260 亿美元，这一增长受到人们对肥胖作为慢性疾病的认识提升以及对 GLP-1 激动剂创新替代品需求增加的推动。</p>
<p>关于 NeuroThera Labs Inc.</p>
<p>NeuroThera Labs Inc.（TSXV：NTLX）是一家临床阶段的制药公司，专注于通过合作和创新组合开发针对中枢神经系统疾病和其他未被充分满足的健康状况的新型治疗药物。</p>
<p>关于 Clearmind Medicine Inc.</p>
<p>Clearmind 是一家临床阶段的神经塑性药物生物技术公司，专注于发现和开发新型的基于迷幻药的治疗，以解决广泛且未被充分满足的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。Clearmind 的知识产权组合目前包括十九个专利系列，拥有 31 项已授予的专利。Clearmind 打算在必要时寻求其化合物的额外专利，并将保持机会主义，以获取额外的知识产权以扩展其组合。Clearmind 的股票在纳斯达克上市，股票代码为 “CMND”。有关更多信息，请访问：https://www.clearmindmedicine.com</p>
<p>如需更多信息，请联系：</p>
<p>Michal Efraty</p>
<p>投资者关系经理</p>
<p>NeuroThera Labs Inc.</p>
<p>电话：+972-3-7617108</p>
<p>电子邮件：michal@efraty.com</p>
<p>TSXV 及其监管服务提供商（根据 TSXV 政策中的定义）对本公告的充分性或准确性不承担任何责任。</p>
<p>前瞻性声明的警示通知</p>
<p>本新闻稿包含构成 “前瞻性信息”（“前瞻性信息”）的声明，符合适用的加拿大证券立法的定义。除历史事实声明外，所有声明均为前瞻性信息，基于截至本新闻稿日期的预期、估计和预测。任何讨论预测、期望、信念、计划、预测、目标、假设、未来事件或表现的声明（通常但不总是使用 “预计”、“不预计”、“预期”、“预期” 或 “不预期”、“计划”、“预算”、“安排”、“预测”、“估计”、“相信” 或 “打算” 等短语，或这些词语和短语的变体，或声明某些行动、事件或结果 “可能” 或 “可以”、“将”、“可能” 或 “会” 发生或实现的声明）均不是历史事实的声明，可能是前瞻性信息。</p>
<p>本新闻稿中的前瞻性信息包括但不限于以下声明：MEAI-PEA 组合在治疗肥胖和代谢功能障碍相关脂肪肝病（MASLD）方面的潜在治疗益处；MEAI-PEA 组合提供比 GLP-1 激动剂更安全、更简单和更具成本效益的替代方案的潜力；组合疗法的假定作用机制；对肥胖和肝脏健康领域新型治疗的预期需求；全球减肥药物市场的增长和未来价值的预测；以及公司推进与 Clearmind Medicine Inc.的合作并将组合疗法开发至商业化的能力。</p>
<p>这些声明并不保证未来的表现，不应过度依赖。此类前瞻性信息必然涉及已知和未知的风险和不确定性，这可能导致公司的实际表现和结果与任何前瞻性信息所表达或暗示的未来表现或结果存在重大差异。</p>
<p>这些风险和不确定性包括但不限于：MEAI-PEA 组合的早期开发阶段及其固有的不确定性，包括临床前和临床结果的不确定性；组合疗法可能未能展示出预期的安全性、有效性或成本效益优势，相较于现有治疗方法，包括 GLP-1 激动剂；公司与 Clearmind Medicine Inc.在可接受条款下推进合作的能力；公司获得所需监管批准的能力；公司获得并维持组合疗法足够专利保护的能力；遵守适用法律法规的能力；公司筹集额外资金以支持未来运营的能力；一般商业、金融市场、经济、竞争、政治和社会的不确定性；以及公司在 SEDAR+ 上公开文件中描述的其他风险和不确定性，网址为 www.sedarplus.ca。</p>
<p>无法保证前瞻性声明将被证明是准确的，实际结果和未来事件可能与预期有重大差异。提醒读者不要对前瞻性信息过度依赖，因为无法保证所依据的计划、意图或期望会发生。尽管管理层在准备时认为这些信息是合理的，但可能会被证明是错误的，实际结果可能与预期有重大差异。除法律要求外，公司不承担更新或修订任何前瞻性信息以反映实际结果的意图和义务，无论是由于新信息、未来事件、假设变化、影响该前瞻性信息的因素变化或其他原因。</p>
<p>版权 (c) 2026 TheNewswire - 保留所有权利。</p>

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

CMND

MNMD

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>NeuroThera Labs Inc. 宣布与 Clearmind Medicine 合作发布了一项国际专利，涉及一种针对减肥和代谢功能障碍相关脂肪肝病（MASLD）的新疗法。5-美氧基-2-氨基吲哚（MEAI）与棕榈酰乙醇胺（PEA）的组合旨在提供一种安全、非致幻的肥胖和 MASLD 治疗方案，以满足预计到 2035 年将达到 2260 亿美元的市场需求。这一合作旨在满足肥胖和肝脏健康领域对有效治疗的需求</p>

<p>(TheNewswire)</p>
<div class="lb-trans"><p>(TheNewswire)</p>
</div><p>Vancouver, British Columbia – March 11, 2026 –TheNewswire – NeuroThera</p>
<div class="lb-trans"><p>温哥华，不列颠哥伦比亚省 –2026 年 3 月 11 日– TheNewswire – NeuroThera</p>
</div><p>Labs Inc.  (the &#34;Company&#34; or&#34;NeuroThera&#34;), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has advanced its collaboration with Clearmind Medicine Inc.with the publication of an international patent application under thePatent Cooperation Treaty (PCT) for a novel combination therapy aimedat treating weight loss and metabolic dysfunction-associated steatoticliver disease (MASLD, formerly known as fatty liver disease).</p>
<div class="lb-trans"><p>Labs Inc.（以下简称 “公司” 或 “NeuroThera”），是一家临床阶段的生物技术公司，且为 SciSparc Ltd.（纳斯达克代码：SPRC）的控股子公司，已通过根据《专利合作条约》（PCT）发布国际专利申请，推进与 Clearmind Medicine Inc.的合作，旨在治疗与体重减轻和代谢功能障碍相关的脂肪肝病（MASLD，前称脂肪肝病）的新型组合疗法。</p>
</div><p>The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)- Palmitoylethanolamide (PEA) combination to offer a safe,non-hallucinogenic neuroplastogen treatment for two major globalhealth challenges: obesity, affecting over 890</p>
<div class="lb-trans"><p>该专利的发布突显了 5-美氧基-2-氨基吲哚（MEAI）与棕榈酰乙醇胺（PEA）组合的潜力，能够为全球面临的两大健康挑战提供安全、非致幻的神经塑性治疗：肥胖，影响全球超过 8.9 亿成年人，以及 MASLD，影响约 30% 的全球成年人口。</p>
</div><p>million adults worldwide, and MASLD,impacting approximately 30% of the global adult</p>
<div class="lb-trans"><p>此外，由于该组合的假定作用机制，这种治疗选择可能比 GLP-1 激动剂提供更安全、更简单和更具成本效益的选择，适用于肥胖和 MASLD。</p>
</div><p>population. Moreover, due to thepresumed mechanism of action of the combination, this therapeuticoption may offer a safer, easier and more cost effective option thanGLP-1s agonists for obesity and MASLD.</p>
<div class="lb-trans"><p>通过将 Clearmind 的 MEAI 平台与 NeuroThera 的 PEA 结合，这两家公司希望满足在肥胖和肝脏健康领域对有效、耐受性好和安全治疗的日益增长的需求。这正值全球减肥药物市场快速增长之际，预计 2025 年市场价值约为 370 亿美元，</p>
</div><p>By combining Clearmind’s MEAI platform withNeuroThera’s PEA, the companies wish to address the escalatingdemand for effective, tolerable and safe treatments in the obesity andliver health space. This comes at a time when the global weight lossdrugs market is experiencing rapid growth, which was valued atapproximately $37 billion in 2025 and</p>
<div class="lb-trans"><p>并预计到 2035 年将达到 2260 亿美元，这一增长受到人们对肥胖作为慢性疾病的认识提升以及对 GLP-1 激动剂创新替代品需求增加的推动。</p>
</div><p>is forecasted to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronicdisease and the need for innovative alternatives to GLP-1agonists.</p>
<div class="lb-trans"><p>关于 NeuroThera Labs Inc.</p>
</div><p>About NeuroThera Labs Inc.</p>
<div class="lb-trans"><p>NeuroThera Labs Inc.（TSXV：NTLX）是一家临床阶段的制药公司，专注于通过合作和创新组合开发针对中枢神经系统疾病和其他未被充分满足的健康状况的新型治疗药物。</p>
</div><p>NeuroThera Labs Inc. (TSXV: NTLX) is aclinical-stage pharmaceutical company focused on developing noveltherapeutics for central nervous system disorders and otherunderserved health conditions through collaborations and innovative combinations.</p>
<div class="lb-trans"><p>关于 Clearmind Medicine Inc.</p>
</div><p>About Clearmind Medicine Inc.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的神经塑性药物生物技术公司，专注于发现和开发新型的基于迷幻药的治疗，以解决广泛且未被充分满足的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。Clearmind 的知识产权组合目前包括十九个专利系列，拥有 31 项已授予的专利。Clearmind 打算在必要时寻求其化合物的额外专利，并将保持机会主义，以获取额外的知识产权以扩展其组合。Clearmind 的股票在纳斯达克上市，股票代码为 “CMND”。有关更多信息，请访问：https://www.clearmindmedicine.com</p>
</div><p>Clearmind is a clinical-stage neuroplastogens pharmaceutical biotechcompany focused on the discovery and development of novelpsychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objectiveis to research and develop psychedelic-based compounds and attempt tocommercialize them as regulated medicines, foods, or supplements.Clearmind’s intellectual portfolio currently consists of nineteenpatent families, including 31 granted patents. Clearmind intends toseek additional patents for its compounds whenever warranted and willremain opportunistic regarding the acquisition of additionalintellectual property to build its portfolio. Shares of Clearmind arelisted for trading on Nasdaq under the symbol &#34;CMND&#34;. Forfurther information, visit: https://www.clearmindmedicine.com</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><p>For further information, please contact:</p>
<div class="lb-trans"><p>Michal Efraty</p>
</div><p>Michal Efraty</p>
<div class="lb-trans"><p>投资者关系经理</p>
</div><p>IR Manager</p>
<div class="lb-trans"><p>NeuroThera Labs Inc.</p>
</div><p>NeuroThera Labs Inc.</p>
<div class="lb-trans"><p>电话：+972-3-7617108</p>
</div><p>Telephone: +972-3-7617108</p>
<div class="lb-trans"><p>电子邮件：michal@efraty.com</p>
</div><p>Email: michal@efraty.com</p>
<div class="lb-trans"><p>TSXV 及其监管服务提供商（根据 TSXV 政策中的定义）对本公告的充分性或准确性不承担任何责任。</p>
</div><p>Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of thisrelease.</p>
<div class="lb-trans"><p>前瞻性声明的警示通知</p>
</div><p>Cautionary Noticeon Forward-Looking Statements</p>
<div class="lb-trans"><p>本新闻稿包含构成 “前瞻性信息”（“前瞻性信息”）的声明，符合适用的加拿大证券立法的定义。除历史事实声明外，所有声明均为前瞻性信息，基于截至本新闻稿日期的预期、估计和预测。任何讨论预测、期望、信念、计划、预测、目标、假设、未来事件或表现的声明（通常但不总是使用 “预计”、“不预计”、“预期”、“预期” 或 “不预期”、“计划”、“预算”、“安排”、“预测”、“估计”、“相信” 或 “打算” 等短语，或这些词语和短语的变体，或声明某些行动、事件或结果 “可能” 或 “可以”、“将”、“可能” 或 “会” 发生或实现的声明）均不是历史事实的声明，可能是前瞻性信息。</p>
</div><p>This press release containsstatements that constitute &#34;forward-looking information&#34;(&#34;forward-looking information&#34;) within the meaning of theapplicable Canadian securities legislation. All statements, other thanstatements of historical fact, are forward-looking information and arebased on expectations, estimates and projections as at the date ofthis news release. Any statement that discusses predictions,expectations, beliefs, plans, projections, objectives, assumptions,future events or performance (often but not always using phrases suchas &#34;expects&#34;, or &#34;does not expect&#34;, &#34;isexpected&#34;, &#34;anticipates&#34; or &#34;does notanticipate&#34;, &#34;plans&#34;, &#34;budget&#34;,&#34;scheduled&#34;, &#34;forecasts&#34;, &#34;estimates&#34;,&#34;believes&#34; or &#34;intends&#34; or variations of suchwords and phrases or stating that certain actions, events or results&#34;may&#34; or &#34;could&#34;, &#34;would&#34;,&#34;might&#34; or &#34;will&#34; be taken to occur or beachieved) are not statements of historical fact and may beforward-looking information.</p>
<div class="lb-trans"><p>本新闻稿中的前瞻性信息包括但不限于以下声明：MEAI-PEA 组合在治疗肥胖和代谢功能障碍相关脂肪肝病（MASLD）方面的潜在治疗益处；MEAI-PEA 组合提供比 GLP-1 激动剂更安全、更简单和更具成本效益的替代方案的潜力；组合疗法的假定作用机制；对肥胖和肝脏健康领域新型治疗的预期需求；全球减肥药物市场的增长和未来价值的预测；以及公司推进与 Clearmind Medicine Inc.的合作并将组合疗法开发至商业化的能力。</p>
</div><p>Forward-looking information in thisnews release includes, without limitation, statements regarding: thepotential therapeutic benefits of the MEAI-PEA combination for thetreatment of obesity and metabolic dysfunction-associated steatoticliver disease (MASLD); the potential for the MEAI-PEA combination tooffer a safer, easier, and more cost-effective alternative to GLP-1agonists; the presumed mechanism of action of the combination therapy;the anticipated demand for novel treatments in the obesity and liverhealth space; projections regarding the growth and future value of theglobal weight loss drugs market; and the Company's ability toadvance the collaboration with Clearmind Medicine Inc. and develop thecombination therapy toward commercialization.</p>
<div class="lb-trans"><p>这些声明并不保证未来的表现，不应过度依赖。此类前瞻性信息必然涉及已知和未知的风险和不确定性，这可能导致公司的实际表现和结果与任何前瞻性信息所表达或暗示的未来表现或结果存在重大差异。</p>
</div><p>These statements are not guaranteesof future performance and undue reliance should not be placed on them.Such forward-looking information necessarily involves known andunknown risks and uncertainties, which may cause the Company'sactual performance and results to differ materially from anyprojections of future performance or results expressed or implied bysuch forward-looking information.</p>
<p>These risks and uncertaintiesinclude, but are not limited to: the early stage of development of theMEAI-PEA combination and the inherent uncertainty of preclinical andclinical outcomes; the risk that the combination therapy may not demonstratethe anticipated safety, efficacy, or cost-effectiveness advantagesover existing treatments, including GLP-1 agonists; the ability of theCompany and Clearmind Medicine Inc. to advance the collaboration onacceptable terms; the ability of the Company to obtain the requiredregulatory approvals; the ability of the Company to obtain andmaintain adequate patent protection for the combination therapy;compliance with applicable laws and regulations; the ability of theCompany to raise additional capital to fund future operations; generalbusiness, financial market, economic, competitive, political andsocial uncertainties; and other risks and uncertainties described inthe Company's public filings available on SEDAR+ at www.sedarplus.ca.</p>
<div class="lb-trans"><p>这些风险和不确定性包括但不限于：MEAI-PEA 组合的早期开发阶段及其固有的不确定性，包括临床前和临床结果的不确定性；组合疗法可能未能展示出预期的安全性、有效性或成本效益优势，相较于现有治疗方法，包括 GLP-1 激动剂；公司与 Clearmind Medicine Inc.在可接受条款下推进合作的能力；公司获得所需监管批准的能力；公司获得并维持组合疗法足够专利保护的能力；遵守适用法律法规的能力；公司筹集额外资金以支持未来运营的能力；一般商业、金融市场、经济、竞争、政治和社会的不确定性；以及公司在 SEDAR+ 上公开文件中描述的其他风险和不确定性，网址为 www.sedarplus.ca。</p>
</div><p>There can be no assurance thatforward-looking statements will prove to be accurate, and actualresults and future events could differ materially from thoseanticipated. Readers are cautioned not to place undue reliance onforward-looking information as there can be no assurance that theplans, intentions or expectations upon which they are placed willoccur. Such information, although considered reasonable by managementat the time of preparation, may prove to be incorrect and actualresults may differ materially from those anticipated. Except asrequired by law, the Company disclaims any intention and assumes noobligation to update or revise any forward-looking information toreflect actual results, whether as a result of new information, futureevents, changes in assumptions, changes in factors affecting suchforward-looking information or otherwise.</p>
<div class="lb-trans"><p>无法保证前瞻性声明将被证明是准确的，实际结果和未来事件可能与预期有重大差异。提醒读者不要对前瞻性信息过度依赖，因为无法保证所依据的计划、意图或期望会发生。尽管管理层在准备时认为这些信息是合理的，但可能会被证明是错误的，实际结果可能与预期有重大差异。除法律要求外，公司不承担更新或修订任何前瞻性信息以反映实际结果的意图和义务，无论是由于新信息、未来事件、假设变化、影响该前瞻性信息的因素变化或其他原因。</p>
</div><p>Copyright (c) 2026 TheNewswire - All rights reserved.</p>
<div class="lb-trans"><p>版权 (c) 2026 TheNewswire - 保留所有权利。</p>
</div>

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

NeuroThera 实验室宣布与 Clearmind Medicine 合作发表国际专利，推出针对减肥和脂肪肝疾病的新疗法